A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

BACKGROUND: Activating events along the PI3K/mTOR pathway are common in head and neck squamous cell carcinomas (HNSCC), and preclinical studies suggest additive or synergistic effects when combining mTORC1 inhibitors with carboplatin and paclitaxel chemotherapy. PATIENTS AND METHODS: In this single-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Dunn, L. A., Fury, M. G., Xiao, H., Baxi, S. S., Sherman, E. J., Korte, S., Pfister, C., Haque, S., Katabi, N., Ho, A. L., Pfister, D. G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834071/
https://ncbi.nlm.nih.gov/pubmed/28961834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx346
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller